Success Metrics

Clinical Success Rate
80.0%

Based on 16 completed trials

Completion Rate
80%(16/20)
Active Trials
17(24%)
Results Posted
25%(4 trials)
Terminated
4(6%)

Phase Distribution

Ph early_phase_1
3
4%
Ph phase_2
23
32%
Ph phase_1
2
3%
Ph not_applicable
10
14%
Ph phase_3
15
21%

Phase Distribution

5

Early Stage

23

Mid Stage

15

Late Stage

Phase Distribution53 total trials
Early Phase 1First-in-human
3(5.7%)
Phase 1Safety & dosage
2(3.8%)
Phase 2Efficacy & side effects
23(43.4%)
Phase 3Large-scale testing
15(28.3%)
N/ANon-phased studies
10(18.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

16 of 20 finished

Non-Completion Rate

20.0%

4 ended early

Currently Active

17

trials recruiting

Total Trials

72

all time

Status Distribution
Active(27)
Completed(16)
Terminated(4)
Other(25)

Detailed Status

unknown25
Completed16
Recruiting16
Not yet recruiting10
Terminated4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
72
Active
17
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (5.7%)
Phase 12 (3.8%)
Phase 223 (43.4%)
Phase 315 (28.3%)
N/A10 (18.9%)

Trials by Status

terminated46%
unknown2535%
not_yet_recruiting1014%
completed1622%
active_not_recruiting11%
recruiting1622%

Recent Activity

Clinical Trials (72)

Showing 20 of 72 trialsScroll for more
NCT06290687Phase 2

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

Recruiting
NCT06386887Not Applicable

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Recruiting
NCT06978322

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

Completed
NCT07217990Phase 1

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Not Yet Recruiting
NCT06914440Phase 2

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Recruiting
NCT07581405Phase 2

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

Not Yet Recruiting
NCT07608159Phase 3

Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.

Not Yet Recruiting
NCT03387553Early Phase 1

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Completed
NCT07570368Not Applicable

Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

Not Yet Recruiting
NCT07413146Not Applicable

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Not Yet Recruiting
NCT07407244Not Applicable

Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer

Active Not Recruiting
NCT06107920Phase 3

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

Recruiting
NCT07383818Phase 2

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Recruiting
NCT00462696Not Applicable

MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer

Completed
NCT07202819Not Applicable

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Recruiting
NCT07081360Phase 3

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

Recruiting
NCT01815853Phase 3

Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Completed
NCT06977893Phase 3

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Recruiting
NCT06712420Phase 3

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

Recruiting
NCT06878222Phase 2

Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
72